GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CASI Pharmaceuticals Inc (NAS:CASI) » Definitions » Cyclically Adjusted Revenue per Share

CASI (CASI Pharmaceuticals) Cyclically Adjusted Revenue per Share : $2.00 (As of Mar. 2025)


View and export this data going back to 1996. Start your Free Trial

What is CASI Pharmaceuticals Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

CASI Pharmaceuticals's adjusted revenue per share for the three months ended in Mar. 2025 was $0.403. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $2.00 for the trailing ten years ended in Mar. 2025.

During the past 12 months, CASI Pharmaceuticals's average Cyclically Adjusted Revenue Growth Rate was 8.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 15.30% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -2.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of CASI Pharmaceuticals was 15.30% per year. The lowest was -17.50% per year. And the median was -11.30% per year.

As of today (2025-06-26), CASI Pharmaceuticals's current stock price is $1.30. CASI Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was $2.00. CASI Pharmaceuticals's Cyclically Adjusted PS Ratio of today is 0.65.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of CASI Pharmaceuticals was 25.59. The lowest was 0.65. And the median was 3.25.


CASI Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for CASI Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CASI Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

CASI Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.36 1.26 1.72 1.87 1.93

CASI Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.84 1.80 1.83 1.93 2.00

Competitive Comparison of CASI Pharmaceuticals's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, CASI Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CASI Pharmaceuticals's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CASI Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where CASI Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


;
;

CASI Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, CASI Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.403/115.1156*115.1156
=0.403

Current CPI (Mar. 2025) = 115.1156.

CASI Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 0.007 99.500 0.008
201509 0.000 100.500 0.000
201512 0.000 100.600 0.000
201603 0.000 102.200 0.000
201606 0.000 101.400 0.000
201609 0.000 102.400 0.000
201612 0.000 102.600 0.000
201703 0.000 103.200 0.000
201706 0.000 103.100 0.000
201709 0.000 104.100 0.000
201712 0.000 104.500 0.000
201803 0.000 105.300 0.000
201806 0.000 104.900 0.000
201809 0.000 106.600 0.000
201812 0.000 106.500 0.000
201903 0.000 107.700 0.000
201906 0.000 107.700 0.000
201909 0.291 109.800 0.305
201912 0.139 111.200 0.144
202003 0.345 112.300 0.354
202006 0.265 110.400 0.276
202009 0.360 111.700 0.371
202012 0.389 111.500 0.402
202103 0.460 112.662 0.470
202106 0.512 111.769 0.527
202109 0.580 112.215 0.595
202112 0.655 113.108 0.667
202203 0.657 114.335 0.661
202206 0.630 114.558 0.633
202209 0.751 115.339 0.750
202212 1.123 115.116 1.123
202303 0.626 115.116 0.626
202306 0.736 114.558 0.740
202309 0.661 115.339 0.660
202312 0.514 114.781 0.515
202403 0.255 115.227 0.255
202406 0.294 114.781 0.295
202409 0.510 115.785 0.507
202412 0.697 114.893 0.698
202503 0.403 115.116 0.403

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


CASI Pharmaceuticals  (NAS:CASI) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

CASI Pharmaceuticals's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1.30/2.00
=0.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of CASI Pharmaceuticals was 25.59. The lowest was 0.65. And the median was 3.25.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


CASI Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of CASI Pharmaceuticals's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


CASI Pharmaceuticals Business Description

Industry
Traded in Other Exchanges
N/A
Address
No. 81, Jianguo Road, Room 1701-1702, China Central Office Tower 1, Huamao Office Building, Chaoyang District, Beijing, CHN, 100025
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.
Executives
James Huang director 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Wei-wu He director, 10 percent owner, officer: Chairman and CEO ENTREMED, INC., 9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Weihao Xu officer: Chief Financial Officer 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Larry Zhang officer: President 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Shrotriya Rajesh C Md director 157 TECHNOLOGY DRIVE, IRVINE CA 92618
Salisbury Franklin Cary Jr director 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Yue Alexander Wu director C/O SORRENTO THERAPEUTICS, INC., 9380 JUDICIAL DRIVE, SAN DIEGO CA 92121
Wealth Strategy Holding Ltd 10 percent owner LEVEL 12, INTERNATIONAL COMMERCE CENTRE, 1 AUSTIN ROAD WEST, HONG KONG K3 HK
Alexander A Zukiwski officer: Chief Medical Officer 200 ROUTE 31 NORTH, SUITE 104, FLEMINGTON NJ 08822
George Chi officer: Chief Financial Officer 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Dapeng Li 10 percent owner BUILDING 1037,XIHU GOLF,, ZHIGANG ROAD 200, HANGZHOU, ZHEJANG F4 310008
Idg-accel China Growth Fund Iii L.p. 10 percent owner UNIT 5505, 55TH FLOOR, THE CENTER, 99 QUEEN'S ROAD K3 00000
Spectrum Pharmaceuticals Inc 10 percent owner 11500 S. EASTERN AVE., SUITE 240, HENDERSON NV 89052
Sparkle Byte Ltd 10 percent owner P.O. BOX 957, OFFSHORE INCORPORATIONS CENTRE ROAD TOWN, TORTOLA D8 00000
Ken Ren director, officer: CEO and Director 3RD FL, BOROUGH A, BLOCK A, NO. 181 SOUTH TAIBAI ROAD, XI'AN, SHAANXI PROVINCE F4 710065